LLRAPC Newsletter – February/March 2023(551 KB) - LMSG/LLR APC newsletters
Date added: 15th Mar 2023
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| Alimemazine (NEW) | Red |
LPT only. Insomnia for new patients (under 18 yr olds) if melatonin and/or another sedating antihistamine has failed or is inappropriate. May be continued into adulthood if patient requires it after transition. |
|
| ALIMEMAZINE (UPDATED) | Do not prescribe | Various |
All other new patients not covered in alternative traffic lights Current patients should be discussed with the prescribing specialist and not have treatment stopped abruptly without appropriate review. |
| AVATROMBOPAG (Doptelet®) (UPDATED) | Red | For treating primary chronic immune thrombocytopenia | |
| DIENOGEST (UPDATED) | Red | Treatment of endometriosis. | |
| ETHAMBUTOL | Red | Tuberculosis treatment |
Red for treatment of TB |
| Hyaluronidase/Trehalose Eye Drops(Thealoz Duo®) (NEW) | Yellow | Ocular Lubricant |
For patients with dexterity issues unable to use 1st line recommendation in ocular lubricant guideline |
| Hydrocortisone Eye Drops(Softacort®) (NEW) | Yellow | Mild non-infectious allergic or inflammatory conjunctival diseases |
When preservative free preparation required |
| Isoniazid | Red | Tuberculosis treatment |
Red for treatment of TB |
| NALOXONE nasal spray (Nyxoid®) (UPDATED) | Red | Opioid overdose |
Turning point or on TTO from secondary care only |
| PENTHROX®(Methoxyflurane) (UPDATED) | Red | Analgesia |
For use in Emergency department or for removal of brachytherapy only |
| PYRAZINAMIDE | Red | Tuberculosis treatment |
Red for treatment of TB |
| Rifampicin | Red | Tuberculosis treatment |
Red for treatment of TB |
| RIFAMPICIN /ISONIAZID AND PYRAZINAMIDE | Red | Tuberculosis treatment |
Red for treatment of TB |
| RIFAMPICIN/ISONIAZID/PYRAZINAMIDE/ETHAMBUTOL (Voractiv) (UPDATED) | Red | Tuberculosis Treatment |
Treatment of TB |
| RIFAXIMIN(Targaxan®) (UPDATED) | Red | Small intestinal overgrowth |
Small intestinal overgrowth |
| Tiopronin (NEW) | Red | Cystinuria | |
| Upadacitinib (Rinvoq®) (NEW) | Red | For treating moderately to severely active ulcerative colitis |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLR APC Meeting Minutes February 2023(253 KB) - LMSG/LLR APC minutes
Date added: 8th Mar 2023
LLR APC Meeting Minutes January 2023(247 KB) - LMSG/LLR APC minutes
Date added: 28th Feb 2023
ABC GUIDE TO MANAGEMENT OF COPD EXACERBATIONS(719 KB) - Guidelines
Uploaded February 2023
Date added: 22nd Feb 2023
TAS Minutes 22nd November 2022(221 KB) - TAS
Date added: 20th Feb 2023
LLR Lipid Pathway(1 MB) - Guidelines
Version 2.1 Uploaded February 2023
Date added: 12th Oct 2022
Interim Inclisiran Pathway(779 KB) - Guidelines
Version 1.1 Uploaded February 2023
Date added: 26th Jul 2022
Neuropathic Pain(339 KB) - Guidelines
Version 3 Uploaded February 2023
Date added: 28th May 2015
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more